AbbVie Inc. (ABBV) vs Merck & Co., Inc. (MRK)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ABBV | MRK |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $61.16B | $65.01B |
| Revenue growth (YoY) | ▲ 8.6% | ▲ 1.3% |
| Net income | $4.23B | $18.25B |
| Gross margin | 70.2% | 74.8% |
| Diluted EPS | $2.36 | $7.28 |
| Insider net (6 mo) | +12.3K sh • 1 sells • 0 buys | −74.8K sh • 9 sells • 0 buys |
| Institutional owners | 46 | 46 |
| Institutional value held | $222.87B | $170.91B |
| Next earnings (est.) | Around Feb 3, 2027 | Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AbbVie Inc. (ABBV)
AbbVie Inc., incorporated in Delaware in 2012, is a global, diversified research-based biopharmaceutical company that became an independent, publicly-traded entity on January 1, 2013, following its spin-off from Abbott Laboratories. Read more →
About Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a global health care company operating through two reportable segments, Pharmaceutical and Animal Health, generating total sales of $64.2 billion in 2024, up from $60.1 billion in 2023 and $59.3 billion in 2022. Read more →
Source: SEC EDGAR.